Levetiracetam for Treatment of Nonpsychotic and Non-depressive behavioural symptoms of dementia.

No registrations found.

| Ethical review | Positive opinion |
|-----------------------|---------------------|
| Status | Recruitment stopped |
| Health condition type | - |
| Study type | Interventional |

Summary

ID

NL-OMON23657

Source Nationaal Trial Register

Brief title LaTiNN

Health condition

3 moths, prospective, open label trial

Sponsors and support

Primary sponsor: Dep geriatrics JBZ
Hervensebaan 4
Postbus 1101 5200 BD Den Bosch
073-6998629
Source(s) of monetary or material Support: UCB for support for statistical analysis if
needed, however Dep geriatrics Utrecht University (Rob van Marum) will first performe this
analysis
Maximum of € 10.000

Intervention

Outcome measures

Primary outcome

Effect on week 4 and 13 compared to base-line on Behauvioral symptoms (NPI and CMAI), care-giver burden (CBI) and clinical impression (GCI).

Secondary outcome

Effect on week 4 and 13 compared to base-line on cognition (MMSE) and ADL (IDDD).

Study description

Background summary

N/A

Study objective

Specific behavioural symptoms of dementia needs specific treatment. In cases, Levetiracetam seems to be effective in Non-psychotic and Non-depressive behavioural symptoms of dementia.

Study design

N/A

Intervention

500 mg Levetiracetam/day, maximum 1500 mg Levetiracetam/day.

Contacts

Public

Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

P.L.J. Dautzenberg Den Bosch 5200 ME The Netherlands +31 (0)73 6998629

2 - Levetiracetam for Treatment of Non-psychotic and Non-depressive behavioural symp ... 21-06-2025

Scientific Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

P.L.J. Dautzenberg Den Bosch 5200 ME The Netherlands +31 (0)73 6998629

Eligibility criteria

Inclusion criteria

- 1. Ambulant patients with dementia, level Reisberg 4-6;
- 2. Informant available.;
- 3. 6 weeks stable treatment of dementia; anti-psychotics and anti-depressants.

Exclusion criteria

- 1. NPI item hallucinations, delusions and depression > ;1
- 2. Epilepsia;
- 3. Alcoholism;
- 4. DM or thyroid disease not under control.

Study design

Design

| Study type: | Interventional |
|---------------------|-------------------------|
| Intervention model: | Other |
| Allocation: | Non controlled trial |
| Masking: | Open (masking not used) |

3 - Levetiracetam for Treatment of Non-psychotic and Non-depressive behavioural symp ... 21-06-2025

Control:

N/A , unknown

Recruitment

| NL | |
|---------------------------|---------------------|
| Recruitment status: | Recruitment stopped |
| Start date (anticipated): | 01-08-2006 |
| Enrollment: | 25 |
| Туре: | Actual |

Ethics review

| Positive opinion | |
|-------------------|------------------|
| Date: | 08-08-2006 |
| Application type: | First submission |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|----------------|
| NTR-new | NL776 |
| NTR-old | NTR787 |
| Other | : N/A |
| ISRCTN | ISRCTN97133543 |

Study results

Summary results

Dautzenberg PLJ et al. Medicamenteuze behaneling van gedrags- en psychische problemen bij dementie (BPSD). Tijdschrift voor verpleeghuisgeneeskunde 2003;27(5):5-9. Weiner MF et al. Levetiracetam for agitated Alzheimer's disease patients. Int J Psychogeriatrics 2005;17(2):327-8.